Factors Affecting the Price of TAZVERIK
TAZVERIK (tazemetostat), an EZH2 inhibitor for epithelial sarcoma and lymphoma, has its price shaped by multiple factors.
Factors Affecting the Price of TAZVERIK
High R&D costs for developing this epigenetic therapy—including clinical trials for rare cancers—drive initial pricing. Patent protection by Epizyme grants market exclusivity, allowing premium rates.
Specialized manufacturing and strict quality control for its capsules add production expenses. Market demand in niche patient populations and regional healthcare policies (e.g., insurance coverage) further influence affordability for patients.
